Please login to the form below

Not currently logged in
Email:
Password:

Pfizer expands generic portfolio

Pfizer has entered into a series of agreements to commercialise several products that have lost market exclusivity in the US and Europe

Pfizer has entered into a series of agreements with India-based, Aurobindo to commercialise several products that have lost market exclusivity in the US and Europe.

The commercialisation will be managed by Pfizer's Established Product Business Unit, which has global annual sales of $10bn. The financial terms of the deal have not been disclosed.

The agreement relates to solid oral dose medicines that are no longer protected by patents and includes 39 products in the US, 20 in Europe including a further 11 in France, covering a broad range of therapeutic areas such as central nervous system disorders and cardiovascular disease. In addition, Pfizer has acquired the rights to 12 sterile injectable antibiotic products in the US and Europe.

"We will dramatically change Pfizer's Established Products portfolio to an engine of positive growth. These agreements represent solid, measurable progress, and a strong commitment to achieve our growth objectives," said David Simmons, president and general manager of Pfizer's Established Products Business Unit.

These agreements build on a five-product US deal agreed between the companies in July 2008.

4th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....
Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...

Infographics